November 10, 2016 - Lipoprotein(a) Foundation Highlights AHA Research Presenting Initial Results of Therapies Under Development to Reduce Lp(a)
Study Published in AHA Journal Demonstrates that Reducing High Lp(a) in those at Highest Risk could have a Significant Impact on the Burden of Cardiovascular Disease
Lancet Reviews Clinical Implications of the Findings from Trials of Two ASOs Targeting Lp(a)
NEW ORLEANS--(BUSINESS WIRE)--The Lipoprotein(a) Foundation is highlighting a number of studies presenting initial results of therapies under development to reduce Lipoprotein(a), also known as Lp(a), at the upcoming American Heart Association’s (AHA) Scientific Sessions 2016, November 12-16, 2016 in New Orleans. Members of The Lipoprotein(a) Foundation’s Scientific Advisory Board were involved with many of the studies being presented, as well as recently published studies that bolster the growing body of research that demonstrates the impact of elevated Lp(a) and its significance as an independent, genetic risk factor for early cardiovascular disease.
The study "Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis," was recently published in the American Heart Association journal, Arteriosclerosis, Thrombosis, and Vascular Biology. With potent Lp(a)-lowering therapies on the horizon, researchers sought to estimate the potential population impact of Lp(a) lowering that may be achieved by these therapies in primary prevention. Results showed that reducing high Lp(a) could potentially prevent up to 1 in 14 cases of myocardial infarction and 1 in 7 cases of aortic valve stenosis. The authors conclude that reducing high Lp(a) in those at highest risk could have a significant impact on the burden of cardiovascular disease.
August 26, 2016 - Lipoprotein(a) Foundation and European Atherosclerosis Society Partner to Raise Awareness of Inherited Cardiovascular Disease and Support Lp(a) Treatment Research
EAS President Dr A.L.Catapano, who has Joined the Lp(a) Foundation Advisory Board, Presents Lipid Control as Part of New European Guidelines at ESC
ROME--(BUSINESS WIRE)--The Lipoprotein(a) Foundation announced today that it has entered into an official partnership with the European Atherosclerosis Society (EAS) to raise awareness for inherited cardiovascular disease and the significance of high Lipoprotein(a) as an independent, genetic risk factor for early cardiovascular disease. The announcement was made here at the European Society of Cardiology (ESC) Congress 2016, August 27-31, 2016.
This week at the ESC 2016 Congress, Dr. Catapano will participate in a session discussing the new 2016 ESC/EAS Guidelines. Focusing on key areas including risk assessment, goals and targets for important cardiovascular risk factors, recommendations for imaging, lipid control, and intervention strategies, the new Guidelines have increased emphasis on Lipoprotein(a): Lipoprotein(a) is a low-density lipoprotein to which an additional protein called apolipoprotein(a) is attached. High concentrations of Lp(a) are associated with increased risk of CAD and ischaemic stroke and Mendelian randomization studies support a causal role in CVD for Lp(a). At present there is no justification for screening the general population for Lp(a), but it may be considered in patients at moderate risk to refine risk evaluation or in subjects with a family history of early CVD.
May 17, 2016 - Lipoprotein(a) Foundation Expands Global Scientific Advisory Board
Advisory Board to Be Actively Involved in the First-Ever Prospective Patient Registry to Study Lp(a) in the U.S. with Recent Grant from NORD in Conjunction with FDA
SAN CARLOS, Calif.--(BUSINESS WIRE)--The Lipoprotein(a) Foundation announced today that it has expanded its global Scientific Advisory Board (SAB) to 27 members. The Advisory Board, comprised of the world’s leading experts on Lipoprotein(a), a highly prevalent, independent, genetic risk factor for early cardiovascular disease, provides support to the Foundation’s mission of saving lives by increasing awareness, advocating for routine testing, and supporting research that will lead to a specific treatment for elevated Lipoprotein(a).
The Lipoprotein(a) Foundation Scientific Advisory Board includes the following third party scientists, lipidologists, cardiologists and healthcare professionals:
- Benoit Arsenault, Ph.D., Universite Laval
- Christie M. Ballantyne, M.D., Baylor College of Medicine
- W. Virgil Brown, M.D., Emory University
- John Chapman, Ph.D., DSc, Pitie-Salpetriere Hospital
- Robert Clarke, M.D., Oxford University
- Tom Dayspring, M.D., True Health Diagnostics
- Keith Ferdinand, M.D., Tulane University,
- Steve Foley, M.D., Comprehensive Women’s Care
- Henry Ginsberg, M.D., Columbia College of Physicians and Surgeons
- Jemma Hopewell, Ph.D., University of Oxford
- Terry Jacobson, M.D., Emory University
- Marlys Koschinsky, Ph.D., Robarts Research Institute, Western University
- Florian Kronenberg, M.D., Medical University of Innsbruck
- Joe McConnell, Ph.D., Salveo Diagnostics
- Catherine J. McNeal, M.D., Ph.D., Baylor Scott & White Health
- Michele Meitus Snyder, M.D., Children’s National Medical Center
- Patrick M. Moriarty, M.D., University of Kansas Hospital
- Pamela Morris, M.D., Medical University of South Carolina
- Borge Nordestgaard, M.D., University of Copenhagen
- Alan Remaley, M.D., Ph.D., National Heart, Lung, Blood
- Raul Santos, M.D., Ph.D., University of Sao Paulo
- Suzanne Shugg, N.P., NJ Cardiology Associates
- Sam Tsimikas, M.D., University of California
- Marina Vernalis, D.O., Walter Reed National Military Medical Center
- Annabelle Santos Volgman, M.D., Rush College of Medicine
- Robert Wild, M.D., Ph.D., University of Oklahoma
- Joseph Witztum, M.D., University of California
In breaking news, the latest issue of The Lancet includes a paper from Advisory Board member Børge G. Nordestgaard, MD, DMSc, of the University of Copenhagen, titled “High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.” The results suggest that high lipoprotein(a) concentrations and corresponding LPA risk genotypes represent novel risk factors for clinical familial hypercholesterolaemia. The authors conclude that all individuals with familial hypercholesterolaemia should have their lipoprotein(a) measured in order to identify those with the highest concentrations, and as a result, the highest risk of myocardial infarction.
The Foundation recently announced that it has received a grant from the National Organization of Orphan Diseases (NORD) in conjunction with the U.S. Food & Drug Administration (FDA), to create the first prospective patient registry to study Lp(a) in the United States by collecting Lp(a) patient histories for research purposes. Members of the Advisory Board will be actively involved in data collection and analysis for the patient registry.
February 25, 2016 - Did You Know That 63 Million Americans Have a High Risk of Inherited Cardiovascular Disease and May Not Know It?
Lp(a) Foundation Issues Heart Month Infographic to Raise Awareness that a Simple Blood Test Could be the First Step in Preventing up to 120,000 Cardiovascular Events Every Year
May 15, 2015 - LIPOPROTEIN (A) FOUNDATION TO AUCTION OFF DONATED TRIUMPH BONNEVILLE T100 TO RAISE AWARENESS FOR STRONGEST INHERITED RISK FOR HEART DISEASE
British Customs Commemorating the Gyronaut X-1 With Custom Build
SAN FRANCISCO – Triumph Motorcycles has donated a new Bonneville T100 motorcycle, customized by British Customs to be unveiled at the 2015 Quail Motorcycle Gathering, Saturday, May 16, 2015 in Carmel, California.
Triumph Motorcycles USA and British Customs have partnered with the Lipoprotein(a) Foundation to help raise awareness for high Lipoprotein(a)[Lp(a)]. The Lipoprotein(a) Foundation is a recognized 501c(3) patient-advocacy non-profit organization.
November 17, 2014 - Lipoprotein(a) Foundation Awarded 501(c)(3) Non-Profit Status
Tax-exempt designation announced at AHA 2014 scientific sessions bolsters
Foundation’s fight against cardiovascular disease and hidden Lp(a) cholesterol risk
CHICAGO — The Lipoprotein(a) Foundation has been granted nonprofit status as a public charity under section 501(c)(3) of the Internal Revenue Service tax code. The announcement was made during the American Heart Association (AHA) Scientific Sessions 2014, at which the foundation is exhibiting in booth No. 1086. The foundation is also holding its first scientific advisory board meeting this evening in Chicago.
November 16, 2013 - HIDDEN HEART RISK REVEALED: NEW NON-PROFIT FOUNDATION EMPOWERS ~ 30% OF AMERICANS AT RISK FOR CARDIOVASCULAR DISEASE TO BE ADVOCATES FOR THEIR CARDIOVASCULAR HEALTH
– “How Could I Have Normal LDL -Cholesterol and Almost Die of a Heart Attack at 39 Years of Age? The Answer: High Lipoprotein(a),” said Sandra Tremulis, Founder, Lipoprotein(a) Foundation –
SAN FRANCISCO CA, U.S.A. (November 16, 2013) – Cardiovascular disease is the #1 killer of Americans, yet 50% of hospital admissions for coronary artery disease have normal LDL-cholesterol.(i) The Lipoprotein(a) Foundation is revealing this hidden risk for patients.